|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM236422847 |
| 003 |
DE-627 |
| 005 |
20241213231819.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2014 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2014.02.015
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1630.xml
|
| 035 |
|
|
|a (DE-627)NLM236422847
|
| 035 |
|
|
|a (NLM)24631965
|
| 035 |
|
|
|a (PII)S1521-6616(14)00052-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Nellore, Anoma
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors
|
| 264 |
|
1 |
|c 2014
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.07.2014
|
| 500 |
|
|
|a Date Revised 13.12.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2014 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Graft versus host disease (GvHD), mediated by donor T cells, remains the primary cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation and novel therapeutic approaches are required. Cdk2 is a critical node of signal integration and programming of T cell responses towards immunity versus anergy but is dispensable for hematopoiesis and thymocyte development. We examined the effects of pharmacologic Cdk2 inhibition on alloreactive human T cells. Inhibition of Cdk2 blocked expansion of alloreactive T cells upon culture with HLA-mismatched dendritic cells and prevented generation of IFN-γ-producing alloantigen-specific effectors. In contrast, Cdk2 inhibition preserved effectors specific for Wilms' tumor 1 (WT1) leukemia antigen and for CMV as determined by WT1-specific and CMV-specific pentamers. Cdk2 inhibition preserved Treg cells, which have the ability to prevent GvHD while maintaining GvL. Thus, Cdk inhibitors may improve allogeneic HSCT by reducing alloreactivity and GvHD without loss of pathogen-specific and leukemia-specific immunity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Cdk2
|
| 650 |
|
4 |
|a Graft versus host disease
|
| 650 |
|
4 |
|a T cells
|
| 650 |
|
4 |
|a T regulatory cells
|
| 650 |
|
7 |
|a Protein Kinase Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Purines
|2 NLM
|
| 650 |
|
7 |
|a WT1 Proteins
|2 NLM
|
| 650 |
|
7 |
|a WT1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Roscovitine
|2 NLM
|
| 650 |
|
7 |
|a 0ES1C2KQ94
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a EZH2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.1.1.43
|2 NLM
|
| 650 |
|
7 |
|a Enhancer of Zeste Homolog 2 Protein
|2 NLM
|
| 650 |
|
7 |
|a EC 2.1.1.43
|2 NLM
|
| 650 |
|
7 |
|a Polycomb Repressive Complex 2
|2 NLM
|
| 650 |
|
7 |
|a EC 2.1.1.43
|2 NLM
|
| 650 |
|
7 |
|a Cyclin-Dependent Kinase 2
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.22
|2 NLM
|
| 700 |
1 |
|
|a Liu, Bianling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Patsoukis, Nikolaos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Boussiotis, Vassiliki A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Lequn
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 152(2014), 1-2 vom: 01. Mai, Seite 48-57
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:152
|g year:2014
|g number:1-2
|g day:01
|g month:05
|g pages:48-57
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2014.02.015
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 152
|j 2014
|e 1-2
|b 01
|c 05
|h 48-57
|